This brand-new, industry-led, three-day summit was the only event entirely dedicated to the strategic application of Model-Informed Drug Development (MIDD). It brought together senior leaders in pharmacometrics, clinical pharmacology, PK/PD, and modeling to explore how MIDD is transforming drug development across therapeutic areas including oncology, CNS, CVRM, RNA, and immunology.

Through case studies, regulator-led sessions, and cross-functional discussions, attendees uncovered practical strategies to bridge the communication gap between modelers and biologists, decode the ICH M15 draft to future-proof regulatory submissions, and see how pioneers are using MIDD to optimize dose selection, reduce patient exposure, and accelerate timelines.

This was your opportunity to benchmark against industry leaders, exchange real-world experiences, and leave with a clear, actionable roadmap to maximize the ROI of MIDD in your own programs.